New nasal spray COVID booster shows promise in early trial

NCT ID NCT06441968

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-stage trial tested a new COVID-19 booster vaccine given as a nasal spray in 60 adults who had already received at least one mRNA COVID-19 booster. The main goal was to check safety and how well the body's immune system responds. The vaccine uses a harmless mouse virus to deliver a piece of the COVID-19 spike protein.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MPV/S-2P (a live virus vaccine given as a nasal spray)
What this could lead to: If successful, this could lead to a new type of COVID-19 booster that is easier to take (nasal spray) and may provide better protection at the site of infection.
What could go wrong: This is an early Phase 1 trial with only 60 people, so it is primarily checking safety, not yet proving effectiveness. The vaccine uses a live virus, which may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030-3411, United States
NYU Grossman Long Island School of Medicine - Vaccine Center

Mineola, New York, 11501, United States
The Hope Clinic of Emory University

Decatur, Georgia, 30030-1705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.